Your browser is no longer supported. Please, upgrade your browser.
Settings
MDXG [NASD]
MiMedx Group, Inc.
Index- P/E- EPS (ttm)-0.77 Insider Own2.50% Shs Outstand110.28M Perf Week14.38%
Market Cap761.92M Forward P/E- EPS next Y-0.07 Insider Trans-0.33% Shs Float108.74M Perf Month22.46%
Income-83.20M PEG- EPS next Q-0.08 Inst Own59.30% Short Float3.22% Perf Quarter-34.05%
Sales261.00M P/S2.92 EPS this Y-221.80% Inst Trans0.15% Short Ratio3.34 Perf Half Y-40.39%
Book/sh-0.06 P/B- EPS next Y53.60% ROA-41.90% Target Price- Perf Year2.58%
Cash/sh0.75 P/C8.96 EPS next 5Y15.00% ROE- 52W Range5.30 - 15.99 Perf YTD-25.55%
Dividend- P/FCF- EPS past 5Y-37.80% ROI-87.00% 52W High-57.72% Beta1.97
Dividend %- Quick Ratio2.70 Sales past 5Y5.80% Gross Margin83.30% 52W Low27.55% ATR0.57
Employees735 Current Ratio2.90 Sales Q/Q27.20% Oper. Margin-15.80% RSI (14)42.52 Volatility4.16% 5.06%
OptionableYes Debt/Eq- EPS Q/Q62.10% Profit Margin-31.90% Rel Volume0.95 Prev Close6.52
ShortableYes LT Debt/Eq- EarningsAug 03 AMC Payout- Avg Volume1.05M Price6.76
Recom2.00 SMA2011.40% SMA50-32.06% SMA200-34.74% Volume997,822 Change3.68%
Jul-26-21Initiated Northland Capital Outperform $23
Mar-19-21Initiated H.C. Wainwright Buy $20
Oct-14-21 04:05PM  
Oct-13-21 07:00AM  
Sep-30-21 11:40AM  
Sep-20-21 09:43AM  
Sep-13-21 12:49PM  
12:17PM  
09:24AM  
08:38AM  
06:30AM  
03:57AM  
Sep-08-21 07:30AM  
Sep-07-21 08:00AM  
Aug-27-21 09:00AM  
Aug-17-21 08:30AM  
Aug-16-21 10:37AM  
Aug-13-21 11:23AM  
Aug-12-21 08:30AM  
Aug-05-21 10:18AM  
Aug-03-21 05:22PM  
Jul-20-21 08:00AM  
Jul-14-21 09:00AM  
Jun-30-21 04:44AM  
Jun-28-21 08:00AM  
Jun-16-21 08:00AM  
Jun-15-21 04:54PM  
Jun-08-21 08:30AM  
May-27-21 08:00AM  
May-25-21 08:30AM  
May-12-21 08:00AM  
May-10-21 08:00AM  
07:05AM  
May-06-21 08:00AM  
May-05-21 10:09AM  
May-04-21 09:15AM  
May-03-21 08:02AM  
May-01-21 04:08AM  
Apr-29-21 06:30AM  
Apr-28-21 05:00PM  
10:21AM  
Apr-23-21 03:25PM  
Apr-22-21 08:00AM  
Apr-20-21 11:38AM  
Apr-19-21 09:00AM  
Apr-16-21 12:07PM  
07:30AM  
Apr-12-21 04:56AM  
Mar-30-21 08:00AM  
Mar-17-21 06:47AM  
Mar-09-21 06:30AM  
Mar-08-21 05:33PM  
05:32PM  
Mar-03-21 08:00AM  
Mar-02-21 08:00AM  
Feb-26-21 03:00AM  
Feb-25-21 03:04AM  
Feb-23-21 05:21PM  
Feb-18-21 09:37AM  
Feb-10-21 08:00AM  
Jan-06-21 08:00AM  
Jan-04-21 08:00AM  
Dec-07-20 08:00AM  
Dec-01-20 09:22AM  
Nov-24-20 05:15PM  
Nov-13-20 08:00AM  
Nov-12-20 08:00AM  
Nov-04-20 04:07PM  
08:00AM  
Nov-03-20 05:30PM  
08:00AM  
Oct-30-20 04:52PM  
Oct-29-20 04:05PM  
Oct-15-20 08:23AM  
Sep-24-20 07:05AM  
Sep-21-20 08:30AM  
06:15AM  
Sep-17-20 11:00AM  
Aug-10-20 09:00AM  
Aug-04-20 05:21PM  
Jul-28-20 07:30AM  
May-05-20 04:30PM  
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stein Robert BenjaminEVP, Research and DevelopmentAug 16Sale11.859,362110,968181,706Aug 17 04:56 PM